Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients
ConditionDiabetes Mellitus
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of Vienna
About this trial
The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.
Eligibility criteria
Qualifiers
Men and women aged ≥ 18 years
Signed informed consent
Previously diagnosed diabetes mellitus
Normal ophthalmic findings except diabetic retinopathy, unless the investigator considers an abnormality to be clinically irrelevant
Disqualifiers
Participation in a clinical trial in the 3 weeks preceding the screening visit
Symptoms of a clinically relevant illness in the 3 weeks before the first study day
Presence or history of a severe medical condition, except diabetes, as judged by the clinical investigator
Abuse of alcoholic beverages
Trial design
Treatments tested in this trial
- • Laser Speckle Flowgraphy (LSFG)
- • Optical Coherence Tomography (OCT)
- • Optical Coherence Tomography Angiography (OCT-A)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov